Metastatic thymic-enteric adenocarcinoma responding to chemoradiation plus anti-angiogenic therapy: A case report

Table 1 Clinicopathologic features of 16 patients with thymic adenocarcinoma as reported in the literature

Case No.	Age	Gender	Ki-67	Treatment	Outcome	Ref.
1	70	Male	20%-30%	Surgery	AWD, 7 mo	[2]
2	59	Female	NA	Surgery + chemoradiotherapy + radiotherapy	Alive with disease, 11 mo (bone and lung metastasis)	[8]
3	41	Female	90%	Surgery	AWD, 18 mo	[9]
4	39	Female	NA	Surgery	AWD, 159 mo (recurrence +)	[9]
5	28	Female	NA	Surgery + chemotherapy (GEMOX) + radiotherapy	AWD, 30 mo (2 times recurrence)	[10]
6	55	Male	NA	Surgery + radiotherapy	AWD, 14 mo	[11]
7	36	Female	NA	Surgery + chemotherapy (Taxol/CDDP) + radiotherapy	DOD, 15 mo	[12]
8	66	Female	NA	Surgery	AWD, 5 yr	[13]
9	NA	NA	NA	Surgery	NA	[14]
10	52	Female	NA	Surgery + chemotherapy (cisplatin + etoposide/carboplatin + paclitaxel) + radiotherapy	Alive with disease, 11 mo (lung and lymph node metastasis)	[15]
11	38	Male	NA	Surgery + radiotherapy + chemotherapy (carboplatin + docetaxel)	DOD, 12 mo (bone metastasis)	[15]
12	55	Male	NA	Surgery + chemotherapy (carboplatin + docetaxel/paclitaxel)	DOD, 24 mo (bone, liver, lung, adrenal gland metastases)	[15]
13	41	Male	NA	Surgery	AWD, 43 mo (lung metastasis+)	[16]
14	34	Male	NA	Surgery + chemotherapy (carboplatin, Adriamycin, cyclophosphamide, and vincristine) + radiotherapy	DOD, 20 mo	[17]
15	15	Male	NA	Surgery + radiotherapy	DOD, 26 mo	[18]
16	29	Female	NA	Surgery	AWD, 8 mo	[19]
Present case	44	Female	70%	Concurrent chemoradiotherapy + antiangiogenic therapy	AWD

AWD: Alive without disease; DOD: Died of disease; NA: Not available; NOS: Not otherwise specified.